(Head and Neck Cancer) Nivolumab Shows Better Quality of Life — ESMO 2016
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Nivolumab vs. Physician's Choice: Quality of Life in Head and Neck Cancer
- October 31, 2016
- Reading time: 2 minutes
This month's final article shares head and neck cancer treatment information from ESMO 2016. Similar data were presented at ASCO 2016 — for patients who relapsed after platinum-based chemotherapy (e.g., carboplatin, cisplatin), nivolumab (Opdivo) provided better quality of life compared to physician's choice chemotherapy. This was presented by K. Harrington of the Institute of Cancer Research, United Kingdom.
CheckMate-141 Trial
The CheckMate-141 trial enrolled patients with head and neck squamous cell carcinoma (HNSCC) who relapsed within 6 months of platinum-based therapy or had metastatic disease. Patients were randomized to nivolumab or physician's choice (docetaxel [DTX], methotrexate [MTX], or cetuximab) in a Phase 3 comparative trial. Patient-reported outcomes (PROs) were assessed using EORTC QLQ-C30, EORTC QLQ-H&N35 (head and neck cancer-specific), and EQ-5D questionnaires, starting at week 9 and then every 6 weeks.
QOL Assessment Results
EORTC QLQ-C30 results: Both groups started at similar levels, but by week 15, the chemotherapy group showed notable deterioration in physical function, social functioning, and other domains — PD-L1 status had no effect on this finding. By week 15, the chemotherapy group showed greater deterioration in symptoms such as cancer fatigue, dyspnea, and decreased appetite compared to the nivolumab group. The median time to sustained deterioration in global health status, physical function, and social functioning was more than twice as long in the nivolumab group compared to the chemotherapy group.
QLQ-H&N35 results: Again, both groups started similarly. From week 15 onward, the chemotherapy group showed worsening pain, physical abnormalities, and social impairment. The nivolumab group showed:
- 74% reduction in pain compared to the chemotherapy group
- 62% reduction in physical abnormalities
- 51% reduction in difficulty opening the mouth
EQ-5D VAS results: At the week 15 time point, the median time to health deterioration was approximately 3 times longer in the nivolumab group compared to the chemotherapy group.
Based on all three assessment tools, nivolumab demonstrated substantially higher quality of life (QOL) outcomes.
Tags: #LungCancer #HeadAndNeckCancer #Immunotherapy
- Immunotherapy
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4